추가 설명:
Combining olmesartan medoxomil with rosuvastatin, this is the world's first fixed-dose combination of the two, indicated for concomitant hypertension and dyslipidemia. Developed using Daewoong's patented formulation technology, it pairs a highly potent ARB with a highly potent statin from their respective drug classes while minimizing drug-drug interactions in metabolism and absorption.
평가 & 댓글 남기기